ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Mok, T., Spigel, D., Felip, E., deMarinis, F., Ahn, M., Groen, H. M., Wakelee, H. A., Hida, T., Crino, L., Nishio, M., Scagliotti, G. V., Branle, F., Emeremni, C., Quadrigli, M., Zhang, J., Shaw, A. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036901771